This website provides educational information about medicines and active ingredients. It does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Pharmacists

Triumeq SmPC: Uses, Ingredients, Safety and FAQs

Quick summary: Triumeq 50 mg/600 mg/300 mg film-coated tablets are used for the treatment of HIV-1 in adults, adolescents, and children who meet the weight criteria in the product information. It contains dolutegravir, abacavir,...

Educational content Use this article as a starting point for understanding the topic.
Check with a professional Ask a doctor or pharmacist before changing any medicine.
Safety first Side effects, interactions and risks depend on each person.
Medical disclaimer

This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.

Quick summary: Triumeq 50 mg/600 mg/300 mg film-coated tablets are used for the treatment of HIV-1 in adults, adolescents, and children who meet the weight criteria in the product information. It contains dolutegravir, abacavir, and lamivudine.

This page gives a clear SmPC-style overview of what Triumeq is used for, what it contains, key precautions, and common questions to check with the official leaflet or a healthcare professional.

Medical disclaimer: This article is for general information only and does not replace the official Summary of Product Characteristics, patient leaflet, or advice from a doctor or pharmacist. HIV treatment decisions, monitoring, and any medicine changes should always be made by a qualified healthcare professional.

What Triumeq is used for

Triumeq is used for the treatment of HIV-1. The current content states that it is used in adults, adolescents, and children weighing over 25 kg.

As with other HIV medicines, treatment is usually part of a wider care plan that may include regular monitoring and follow-up appointments.

Before starting treatment, the original content notes that HLA-B*5701 testing is required because of the abacavir component.

What Triumeq contains

Triumeq contains three active ingredients:

  • Dolutegravir
  • Abacavir
  • Lamivudine

These ingredients work together as a combination treatment for HIV-1.

How the ingredients are described in the source content

  • Dolutegravir: described as an integrase strand transfer inhibitor.
  • Abacavir: described as a nucleoside reverse transcriptase inhibitor (NRTI).
  • Lamivudine: also described as an NRTI.

How Triumeq is taken

The source content states that Triumeq can be taken with or without food.

It also states that the general recommended dose is one tablet once daily for people who meet the weight criteria in the product information.

For exact dosing instructions, timing, and suitability, readers should check the official SmPC or ask a healthcare professional.

Topic What the current content says
Use Treatment of HIV-1
Ingredients Dolutegravir, abacavir, lamivudine
Administration Can be taken with or without food
General dosing One tablet once daily, subject to product criteria

Precautions and monitoring

The original content highlights several precautions that should be checked before and during treatment.

  • HLA-B*5701 testing: noted as important before starting Triumeq.
  • Medical history: patients should disclose allergies and existing health conditions.
  • Kidney and liver monitoring: regular blood tests may be used to monitor function.
  • Renal impairment: the source content says Triumeq should not be used in severe renal impairment without special considerations.

If there is any uncertainty about suitability, the official product information and a healthcare professional should be consulted.

Possible side effects

The current content lists the following possible side effects:

  • Nausea
  • Headache
  • Fatigue
  • Insomnia

It also notes that serious problems may include hypersensitivity reactions, liver problems, or changes in kidney function.

Any unusual or concerning symptoms should be discussed promptly with a healthcare professional, especially if an allergic reaction is suspected.

Who should check the official leaflet carefully

Because the source content is a summary rather than the full SmPC, readers should verify the following in the official leaflet or with a pharmacist:

  • Whether Triumeq is appropriate for the patient’s age and weight
  • Whether HLA-B*5701 testing has been completed
  • Any kidney or liver monitoring requirements
  • How the tablet should be taken in the individual treatment plan
  • Any medicine interactions or special precautions listed in the official product information

Frequently asked questions

▸ What is Triumeq used for?

Triumeq is used for the treatment of HIV-1 in adults, adolescents, and children who meet the weight criteria mentioned in the source content.

▸ What ingredients are in Triumeq?

Triumeq contains dolutegravir, abacavir, and lamivudine.

▸ Can Triumeq be taken with food?

The source content says Triumeq can be taken with or without food.

▸ What testing is mentioned before starting Triumeq?

The content states that HLA-B*5701 testing is required before starting Triumeq because of the abacavir component.

▸ What side effects are listed in the summary?

The summary lists nausea, headache, fatigue, and insomnia, and notes that hypersensitivity reactions, liver problems, and kidney changes may also occur.

▸ Where should I check the full prescribing details?

Check the official Summary of Product Characteristics and patient leaflet, or ask a doctor or pharmacist for advice tailored to the individual patient.

Safety reminder

Do not rely on this summary alone for treatment decisions. HIV medicines require professional supervision, and the official product information should be checked for the most complete and current details.

If symptoms suggest a serious reaction, or if there are concerns about kidney, liver, or allergy-related issues, seek medical advice promptly.

Editorial note Active Ingredients Online Editorial Team This article is prepared as educational medicine information for general readers. It is written to support understanding of active ingredients, medicine uses, possible side effects, precautions and safety-related questions.
Published: November 30, 2024 Updated: August 17, 2026 Educational content

Medical disclaimer

This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.

Final note

Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.

Ask a Doctor Online medical questions